{'fraction_non_alphanumeric': 0.034594594594594595, 'fraction_numerical': 0.016216216216216217, 'mean_word_length': 5.962406015037594, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Glutoxim in the surgical treatment of patients with pulmonary tuberculosis].

Surgery results in the development of secondary immunodeficiency associated with inhibition of the phagocytic bactericidal systems, leading to postoperative complications. Glutoxim, a representative of thiopoietins, was used to reduce the number of postoperative complications. Twenty-nine patients with pulmonary tuberculosis received glutoxim therapy (a study group). A control group comprised 25 patients. A course of glutoxim therapy was 35 days; the daily dose was 60 mg. Postoperative complications (tuberculous pleural empyema with bronchopleural fistula, progressive tuberculosis, nonspecific pneumonias) developed in 2 (6.9%) study group patients and in 8 (32%) control ones (p < 0.05). The inclusion ofglutoxim into complex preoperative preparation and its postoperative use cause a significant reduction in postoperative complications.